fMRI ­Data from Clinical Trial Demonstrate a Proposed Mechanism of Action for the Efficacy of Vayarin® Plus in Adults with ADHD Study Abstract Presented at the 2019 APSARD Annual Meeting in Washington, DC COLUMBIA, Md., Jan. 22, 2019 (GLOBE NEWSWIRE) -- VAYA™ Pharma, Inc. (VAYA™), a division of Frutarom, Inc, and...

CORRECTING and REPLACING -- Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study BALTIMORE, Jan. 24, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline January 10, 2017 by VAYA Pharma, please note that in the first paragraph under Results at a Glance, "38...

Improved Academic Performance and Medication Rebound in Patients with ADHD Following the Use of Vayarin®, a Multi-Year, Real-World Retrospective Study BALTIMORE, Jan. 10, 2017 (GLOBE NEWSWIRE) -- Up to 75 percent of individuals with Attention Deficit Hyperactivity Disorder (ADHD) experience emotional dysregulation, according to Research in...